A Case of Novel Combination Therapy for Refractory Lupus Nephritis (KIDNEY WEEK 2025) - Oct 18, 2025 - Abstract #FR-PO0916; Pres time: Nov 7, 2025; 10:00 AM - 12:00 PM; Location: Exhibit Hall, Convention Center; "She was treated with mycophenolate mofetil (MMF), hydroxychloroquine, and prednisone but required frequent steroids for persistent symptoms and serologic activity. She had an allergic reaction to rituximab and no response to 14 months of belimumab...She received six months of cyclophosphamide, with ocrelizumab later added due to poor response...Discussion In patients with LN who have suboptimal response to MMF/cyclophosphamide and prednisone, current literature recommends addition of voclosporin if high proteinuria or belimumab if prior flares...Belimumab therapy is known to have good serological and extrarenal outcomes (BLISS-LN). Our patient did not respond to either therapies individually with MMF and steroid; however, the novel combination of both achieved both clinical and serological remission for the first time in her 10 years of complicated SLE and LN history."
Clinical • Combination therapy • Acute Kidney Injury • Cardiovascular • Glomerulonephritis • Hypertension • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease • Systemic Lupus Erythematosus • Vasculitis
|
|
Daniel P. Gulden; Madison B. Calder; Shweta Bansal
|